Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|June 17, 2022
MHRA to Play Greater Role in International Medicines Regulation
Author(s)Pharmaceutical Technology Editors
MHRA has been accepted as a full member of three international work-sharing partnerships aimed at making sure medicines and medical devices are regulated safely and efficiently across the world.
Advertisement
The United Kingdom’s regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has been accepted as a full member of three international work-sharing partnerships aimed at making sure medicines and medical devices are regulated safely and efficiently across the world.
Two of the bodies that MHRA will join are the International Medical Device Regulatory Forum (IMDRF) and the International Council for Harmonisation (ICH), which are concerned with the harmonization of medicines and medical devices regulations globally. The third body is the Medical Devices Innovation Consortium (MDIC), which is an American public-private partnership aimed at progressing innovation and getting transformational medical technology to people sooner.
“We are delighted to join these three international organizations to collaborate on regulatory alignment that will help deliver safer, innovative, and more cost-effective medicines and medical devices to the people who need them sooner,” said Glenn Wells, chief international and partnerships officer at the MHRA, in a June 16, 2022 press release.
“We are currently building a world-leading regime for regulating medicines and medical devices in the UK that prioritises patient safety while fostering innovation, and we look forward to sharing expertise with partner organisations for the benefit of patients not just in the UK but worldwide.”
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement